BRIEF—Enzyvant appoints new CEO

Roivant Sciences subsidiary Enzyvant has appointed Rachelle Jacques as chief executive. Ms Jacques was previously senior VP at Alexion and has worked as VP of Shire’s US hematology marketing division.

Ms Jacques replaces Alvin Shih, who has served as chief executive since the rare disease specialist was founded in 2016. Dr Shih will continue to be an advisor to the company.

Chairperson Myrtle Potter said: "We are thrilled that Rachelle is joining Enzyvant as the company prepares for the potential commercialization of Enzyvant's first therapy."